Angiogenesis and thyroid cancer;Angiogenèse et cancer de la thyroïde

Presse Medicale

Volumn 38, Issue 11, 2009, Pages 1641-1646

  Francis, Zelia ^a   Baudin, Eric ^a   Leboulleux, Sophie ^a   Schlumberger, Martin ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; GEFITINIB; IMATINIB; LENALIDOMIDE; MOTESANIB; PACLITAXEL; SORAFENIB; SUNITINIB; THALIDOMIDE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; XL 184;

ANTIANGIOGENIC ACTIVITY; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; FOLLICULITIS; GENE MUTATION; HUMAN; INFECTION; MALAISE; MOLECULAR GENETICS; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; SHORT SURVEY; SKIN TOXICITY; SOMNOLENCE; THYROID CANCER; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; THYROID NEOPLASMS;

EID: 71549137753     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.10.026     Document Type: Short Survey

References (30)

1. Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Engl J Med 338 (1998) 297-306
2. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., et al. Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91 (2006) 2892-2899
3. Baudin E., and Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8 (2007) 148-156
4. De Crevoisier R., Baudin E., Bachelot A., Leboulleux S., Travagli J.P., Caillou B., et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiation Oncology Biol Phys 60 (2004) 1137-1143
5. Schlumberger M., Carlomagno F., Baudin E., Bidart J.M., and Santoro M. New therapeutic approaches for medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4 (2008) 22-32
6. Kondo T., Ezzat S., and Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6 (2006) 292-306
7. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13 (2007) 1161-1170
8. Fagin J.A. How thyroid tumors start and why it matters : kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183 (2004) 249-256
9. Bunone G., Vigneri P., Mariani L., Butó S., Collini P., Pilotti S., et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155 (1999) 1967-1976
10. Klein M., Vignaud J.M., Hennequin V., Toussaint B., Bresler L., Plenat F., et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86 (2001) 656-658
11. Lennard C.M., Patel A., Wilson J., Reinhardt B., Tuman C., Fenton C., et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129 (2001) 552-558
12. Fenton C., Patel A., Dinauer C., Robie D.K., Tuttle R.M., and Francis G.L. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 10 (2000) 349-357
13. Bauer A.J., Patel A., Terrell R., Doniparthi K., Saji M., Ringel M., et al. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. Ann Clin Lab Sci 33 (2003) 192-199
14. Bauer A.J., Terrell R., Doniparthi N.K., Patel A., Tuttle R.M., Saji M., et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12 (2002) 953-961
15. Cohen E.E.W., Rosen L.S., Vokes E.E., Kies M.S., Forastiere A.A., Worden F.P., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer : results from a phase II study. J Clin Oncol 26 (2008) 4708-4713
16. Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., et al. Phase II trial of Sorafenib in advanced thyroid cancer. J Clin Oncol 26 (2008) 4714-4719
17. Kloos R., Ringel M., Knopp M., Heverhagen J., Rittenberry J., Weldy L., et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC) : updated results of a phase II study. J Clin Oncol 24 (2006) 5534
18. Cohen EEW, Needles BM, Cullen KJ, Wong S, Wade J, Ivy P et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008 (meeting abstracts);26:6025.
19. Sherman S.I., Wirth L.J., Droz J.P., Hofmann M., Bastholt L., Martins R.G., et al. Motesanib Diphosphate in Progressive. Differentiated Thyroid Cancer. N Engl J Med 359 (2008) 31-42
20. Ain K.B., Lee C., and Williams K.D. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17 (2007) 663-670
21. Wells S, Gosnell J, Gagel R, Moley JF, Pfister DG, Sosa JA et al. Vandetanib in metastatic hereditary medullary thyroid cancer : Follow-up results of an open-label phase II trial. J Clin Oncol 2007 (ASCO Annual Meeting Proceedings Part I.);25:6018.
22. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janish L et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 2008; 26, abstract 3522.
23. Schlumberger M., Elisei R., Sherman S., Bastholt L., Wirth L., Martins R., et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with medullary thyroid cancer. 89th annual meeting of the Endocrine Society (ENDO 07). June 2-5, Toronto, ON (2007)
24. Kober F, Hermann M, Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 2007 (ASCO Annual Meeting Proceedings Part I);25:14065.
25. Cooney M, Savvides P, Agarwala S, Wang D, Flick S, Bergan S et al. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol 2006 (ASCO Annual Meeting Proceedings Part I.);24:5580.
26. Frank-Raue K., Fabel M., Delorme S., Haberkorn U., and Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 157 (2007) 215-220
27. de Groot J.W., Zonnenberg B.A., van Ufford-Mannesse P.Q., de Vries M.M., Links T.P., Lips C.J., et al. A phase-II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92 (2007) 3466-3469
28. Pennell N.A., Daniels G.H., Haddad R.I., Ross D.S., Evans T., Wirth L.J., et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18 (2008) 317-323
29. Desai J., Yassa L., Marqusee E., George S., Frates M.C., Chen M.H., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 (2006) 660-664
30. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362